Library · Reproductive · Hormone-dependent cancer and reproductive disorders treatment
Leuprolide Acetate (Lupron, Eligard)
Lupron, Eligard, Leuprorelin acetate, Lucrin
Synthetic GnRH agonist from 1985 (Lupron, Eligard), more potent and longer-lasting than natural GnRH. Approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, available in daily, monthly, and extended-release forms.
Research score 95/100. Reference only, not a dose.
- Hormone Regulation
- Anti-cancer
- Fertility Enhancement
- Inflammation Resolution
- US status
- Prescription Only
- Approval
- FDA + EMA Approved
- Evidence
- FDA-approved GnRH agonist. Standard of care for advanced prostate cancer, endometriosis, and central precocious puberty.
- Research score
- 95 / 100
- Indication
- Prostate Cancer
- Origin
- USA
- Source category
- Reproductive System
- Status group
- Approved / prescription
Mechanism
Initially stimulates LH/FSH release via Gq/11-coupled GnRH receptor activation, but continuous dosing desensitizes and internalizes the receptors, producing reversible medical castration by suppressing sex hormone production.
Safety file
Common effects include hot flashes, injection-site pain, and fatigue; serious risks include an initial tumor flare, bone density loss, metabolic syndrome, and depression or other psychiatric effects.
- Hot flashes
- Mood changes
- Bone density decrease
- Initial hormone flare
- Injection site reactions
- Sexual dysfunction
- Fatigue
- Joint pain